Michelle K Kim, MD
- ASSOCIATE PROFESSOR | Medicine, Gastroenterology
Dr. Kim completed her undergraduate and medical degrees at Harvard College and Stanford University School of Medicine. After completing her medical training at New York–Presbyterian Hospital (Cornell), Dr. Kim joined the faculty at Mount Sinai School of Medicine. Since then, Dr. Kim’s clinical and research interests have dovetailed in gastrointestinal cancers, with specific expertise in carcinoid and neuroendocrine tumors. Dr. Kim is known nationally and internationally for her work in translational and epidemiologic approaches in assessing outcomes in patients with these tumors. Dr. Kim has received multiple research grants including the NIH KL2 Award and a Mentored Career Development Award from the American Cancer Society. Dr. Kim has also won numerous teaching awards and mentored dozens of trainees who have become junior faculty at other academic institutions. Dr. Kim is currently serving as Councilor in the American Gastroenterology Association and has served as Past President of the New York Society for Gastrointestinal Endoscopy.
- Colon Polypectomy
- Endoscopic Ultrasonography
- Pancreatic Cancer
- Upper GI Endoscopy
MD, Stanford University School of Medicine
Residency, Internal Medicine, New York Presbyterian - Weill Cornell Medical Center
Fellowship, Gastroenterology, New York Presbyterian - Weill Cornell Medical Center
Mentored Career Development
- Endoscopic Ultrasound
- Neuroendocrine Tumors/Carcinoid
- Gastrointestinal malignancies
- A Multicenter Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
The study will be conducted as a multicenter open-label long-term extension study to further evaluate long-term safety and tolerability of telotristat etiprate. Patients currently participating in any LX1606 Phase 2 carcinoid syndrome (CS) study may enter into this extension s...
- A Phase 3 Prospective, Randomized, Double-Blind, Multi-Center, Phase 2 Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo for Tumor Control in Patients with well Differentiated, Advanced Lung or Thymus Neuroendocrine Tumors (SPINET)
The purpose of this study is to ascertain the role of Lanreotide Autogel/Depot plus BSC in the management of advanced or metastatic lung or thymus neuroendocrine tumors (NETs). There have been very limited data in this patient setting, except for sub-analyses of larger randomi...